Nuvation Bio Inc. ( NUVB ) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals ( ACAD ) Tops Q2 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Nuvation Bio ( NUVB ) Rating Upgrade to Buy
Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Nuvation Bio ( NYSE:NUVB )
Ibtrozi showed 90% and 85% confirmed response rates in TKI-naïve patients in two separate trials. Intracranial responses were seen in 73% of TKI-naïve and 63% of TKI-pretreated patients. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. The U.S.
Nuvation Bio Inc. ( NUVB ) Reports Q1 Loss, Tops Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0% and 23.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Apple To $280? Here Are 10 Top Analyst Forecasts For Thursday - Apple ( NASDAQ:AAPL ) , Amphenol ( NYSE:APH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised the price target for Amphenol Corporation APH from $85 to $89.
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday - Cintas ( NASDAQ:CTAS ) , Aurora Innovation ( NASDAQ:AUR )
U.S. stocks were lower, with the Nasdaq Composite falling around 150 points on Tuesday. Shares of UniFirst Corporation UNF rose sharply during Tuesday's session after Cintas CTAS submitted a proposal to acquire the company for $275 per share. UniFirst shares jumped 31.8% to $223.18 on Tuesday.
Top 4 Health Care Stocks That May Plunge This Quarter - AirSculpt Technologies ( NASDAQ:AIRS )
As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday - Fastenal ( NASDAQ:FAST )
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Friday. Shares of Fastenal Company FAST rose sharply during Friday's session after the company reported better-than-expected third-quarter financial results.
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Oracle ( NYSE:ORCL )
Shares of Oracle Corporation ORCL rose sharply in today's pre-market trading after the company reported better-than-expected earnings and sales results for its first quarter on Monday.
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data - Nuvation Bio ( NYSE:NUVB )
In its second-quarter earnings release, Nuvation Bio Inc. NUVB announced that it has decided to halt work on NUV-868, its BD2-selective BET inhibitor, while considering the program's future.
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - NeuroBo Pharmaceuticals ( NASDAQ:NRBO )
The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday - AMC Enter Hldgs ( NYSE:AMC ) , Alvotech ( NASDAQ:ALVO )
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday. Shares of Fifth Third Bancorp FITB rose during Friday's session after the company reported better-than-expected quarterly financial results.
ProfoundBio Discovers The Joys Of Having A Wealthy Owner - Genmab ( NASDAQ:GMAB ) , ArriVent BioPharma ( NASDAQ:AVBP )
Cancer treatment maker ProfoundBio announced it will be purchased by Denmark's Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation ( NASDAQ:INTC ) fell sharply in today's pre-market trading after the company outlined a new financial framework for its foundry business.
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Intel ( NASDAQ:INTC )
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation INTC fell sharply in today's pre-market trading after the company outlined a new financial framework for its foundry business.
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday - Cintas ( NASDAQ:CTAS ) , Noah Holdings ( NYSE:NOAH ) , PaySign ( NASDAQ:PAYS )
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation CTAS rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results and raised FY24 guidance.
Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday - Netflix ( NASDAQ:NFLX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays cut the price target for Prologis, Inc. PLD from $153 to $141.
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket - MariaDB ( NYSE:MRDB )
Shares of MariaDB plc MRDB rose sharply in today's pre-market trading after Progress Software PRGS announced that it is possibly considering an offer for the company. MariaDB shares jumped 100.4% to $0.4530 in pre-market trading Here are some other stocks moving in pre-market trading.
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday - Tesla ( NASDAQ:TSLA ) , McCormick & Co ( NYSE:MKC ) , Krispy Kreme ( NASDAQ:DNUT )
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Tesla Inc TSLA rose sharply during Tuesday's session amid reports suggest Italy has approached the company about electric truck production.
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session - Esperion Therapeutics ( NASDAQ:ESPR ) , Masimo ( NASDAQ:MASI )
U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday. Shares of Esperion Therapeutics, Inc. ESPR rose sharply in today's pre-market trading. The U.S.
Nuvation Bio Inc. ( NUVB ) Is Up 25.28% in One Week: What You Should Know
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nuvation Bio Inc. ( NUVB ) Is Up 25.28% in One Week: What You Should Know
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
Nuvation Bio Inc. ( NYSE: NUVB ) , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of ... Investing News Network ...
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
WALTHAM, Mass., Dec. 04, 2023 ( GLOBE NEWSWIRE ) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology ( I&I ) directed therapies, today announced the appointment of Jennifer Fox as its Chief ...
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate ( DDC ) clinical candidate by year end 2023
Nuvation Bio And 3 Other Stocks Under $4 Insiders Are Buying - Eos Energy Enterprises ( NASDAQ:EOSE ) , Cadiz ( NASDAQ:CDZI )
The Dow Jones closed lower by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...
Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim
Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight ... PR ...
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate ( DDC ) clinical candidate by year end 2023
Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer - Black Diamond Therapeutic ( NASDAQ:BDTX )
CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. ( NYSE: NUVB ) , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today ...
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate ( DDC ) clinical candidate by year end 2023
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive ... PR ...
Stocks That Hit 52-Week Lows On Tuesday - SoundHound AI ( NASDAQ:SOUN ) , Sonnet BioTherapeutics ( NASDAQ:SONN )
During Tuesday's trading, 160 companies set new 52-week lows. Tesla TSLA is the largest company in terms of market cap to set a new 52-week low this morning. The smallest company by market cap to set a new 52-week low was Baudax Bio BXRX.
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
UBS cut the price target for Coupa Software Incorporated COUP from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading. Morgan Stanley raised the price target on McKesson Corporation MCK from $370 to $403. McKesson shares fell 0.3% to $369.99 in pre-market trading.
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
Completed business combination with Social Capital Suvretta Holdings, III Completed business combination with Social Capital Suvretta Holdings, III ...
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ...
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. and NEW YORK, Aug. 09, 2022 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc. ( Nasdaq: BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the second quarter ended June 30, ...
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $703.8 million as of June 30, 2022
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate ( DDC ) platform Company restructuring and cost savings associated with NUV-422 program discontinuation to ...
After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program
Nuvation Bio Inc NUVB will discontinue the clinical development of NUV-422 after an internal risk-benefit analysis factoring in feedback from the FDA in a partial clinical hold letter for monotherapy Phase 1/2 study and clinical hold letters for its combination Phase 1b/2 studies.
Nuvation Bio Inc. ( NUVB ) Upgraded to Buy: What Does It Mean for the Stock?
Nuvation Bio Inc. (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III
ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol "PROK" on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund Phase 3 study of REACT™
Short Volatility Alert: Nuvation Bio Inc.
On Friday, shares of Nuvation Bio Inc. NUVB experienced volatile short activity. After the activity, the stock price went up +0% to $4.04. The overall sentiment for NUVB has been Bearish. The signal from the volatility alert is trending Bullish. Therefore, the recommendation is to Decrease Short ...
Nuvation Bio, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 05, 2022 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Nuvation Bio Inc. ( "Nuvation" or "the Company" ) NUVB investors that the firm has initiated an investigation into possible ...
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency has recommended the approval of Enhertu ( trastuzumab deruxtecan ) and Lynparza ( olaparib ) for breast cancer settings.
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
The FDA has placed a partial clinical hold on Nuvation Bio Inc's NUVB Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose.
